The Differences Between IOs and Anti-Pd1 Drugs

I think structurally, you know, there's subtle differences. We tend to end up going with wherever the first one gets to a particular indication. And then we stick with that because we become creatures of habit. But for now, it's hard to say clearly that one is better than another in a different setting. Luis, what are your thoughts about this strategy? What are the situations where right now you think it's reasonable to think about it? And any difference in your mind between Ipenevo and Dervatremi?